SG10201704214VA - Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases - Google Patents
Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseasesInfo
- Publication number
- SG10201704214VA SG10201704214VA SG10201704214VA SG10201704214VA SG10201704214VA SG 10201704214V A SG10201704214V A SG 10201704214VA SG 10201704214V A SG10201704214V A SG 10201704214VA SG 10201704214V A SG10201704214V A SG 10201704214VA SG 10201704214V A SG10201704214V A SG 10201704214VA
- Authority
- SG
- Singapore
- Prior art keywords
- oncology
- antibodies
- extended
- life
- treatment
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 title 1
- 238000001727 in vivo Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14810609P | 2009-01-29 | 2009-01-29 | |
US18418209P | 2009-06-04 | 2009-06-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201704214VA true SG10201704214VA (en) | 2017-06-29 |
Family
ID=42396023
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2014007637A SG2014007637A (en) | 2009-01-29 | 2010-01-29 | Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases |
SG2011046265A SG172354A1 (en) | 2009-01-29 | 2010-01-29 | Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases |
SG10201704214VA SG10201704214VA (en) | 2009-01-29 | 2010-01-29 | Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2014007637A SG2014007637A (en) | 2009-01-29 | 2010-01-29 | Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases |
SG2011046265A SG172354A1 (en) | 2009-01-29 | 2010-01-29 | Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases |
Country Status (14)
Country | Link |
---|---|
US (3) | US20120034212A1 (en) |
EP (1) | EP2391384A4 (en) |
JP (3) | JP2012516158A (en) |
KR (1) | KR20110108398A (en) |
CN (2) | CN102387814A (en) |
AU (1) | AU2010208125B2 (en) |
BR (1) | BRPI1007005A2 (en) |
CA (1) | CA2749200A1 (en) |
HK (1) | HK1201847A1 (en) |
MX (1) | MX337590B (en) |
RU (2) | RU2011135422A (en) |
SG (3) | SG2014007637A (en) |
WO (1) | WO2010088444A1 (en) |
ZA (2) | ZA201104796B (en) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200831528A (en) | 2006-11-30 | 2008-08-01 | Astrazeneca Ab | Compounds |
US20120034212A1 (en) * | 2009-01-29 | 2012-02-09 | Michael Bowen | Human Anti-IL-6 Antibodies With Extended In Vivo Half-Life And Their Use In Treatment Of Oncology, Autoimmune Diseases And Inflammatory Diseases |
US9265834B2 (en) | 2009-03-05 | 2016-02-23 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
WO2010100135A1 (en) | 2009-03-05 | 2010-09-10 | Ablynx N.V. | Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof |
EP2473528B1 (en) * | 2009-09-03 | 2014-12-03 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
WO2012032181A2 (en) | 2010-09-10 | 2012-03-15 | Allozyne, Inc | Novel antibody derivatives |
AU2011349049B2 (en) * | 2010-12-22 | 2016-08-11 | Teva Pharmaceuticals Australia Pty Ltd | Modified antibody with improved half-life |
BR112013018932B1 (en) | 2011-02-10 | 2020-11-17 | Roche Glycart Ag | mutant interleukin-2 (il-2) polypeptide, immunoconjugate, isolated polynucleotide, host cell of microorganisms, method of producing a mutant il-2 polypeptide, pharmaceutical composition and uses of the mutant il-2 polypeptide or immunoconjugate |
CA2827581A1 (en) | 2011-03-03 | 2012-09-07 | Apexigen, Inc. | Anti-il-6 receptor antibodies and methods of use |
EA201892619A1 (en) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | IMMUNOCONJUGATES CONTAINING INTERLEUKIN-2 MUTANT POLYPETIPS |
WO2013047748A1 (en) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
TWI812924B (en) | 2011-09-30 | 2023-08-21 | 日商中外製藥股份有限公司 | Antigen-binding molecules that promote antigen disappearance |
CN104093424A (en) | 2011-09-30 | 2014-10-08 | 中外制药株式会社 | Antigen-binding molecule inducing immune response to target antigen |
SG11201405137QA (en) | 2012-02-24 | 2014-12-30 | Chugai Pharmaceutical Co Ltd | ANTIGEN-BINDING MOLECULE FOR PROMOTING DISAPPEARANCE OF ANTIGEN VIA FcγRIIB |
WO2013175276A1 (en) | 2012-05-23 | 2013-11-28 | Argen-X B.V | Il-6 binding molecules |
ES2662020T3 (en) * | 2012-10-22 | 2018-04-05 | Fountain Biopharma Inc. | Antibodies against interleukin-6 and its uses |
AU2013334740A1 (en) * | 2012-10-25 | 2015-04-02 | Medimmune, Llc | Stable, low viscosity antibody formulation |
US10772940B1 (en) * | 2012-12-11 | 2020-09-15 | University Of Kentucky Research Foundation | Cocaine hydrolase-FC fusion proteins for cocaine and methods for utilizing the same |
WO2014096672A1 (en) * | 2012-12-17 | 2014-06-26 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Use of monoclonal antibodies for the treatment of inflammation and bacterial infections |
FR2999431B1 (en) * | 2012-12-17 | 2016-03-18 | Lfb Biotechnologies | USE OF MONOCLONAL ANTIBODIES FOR THE TREATMENT OF INFLAMMATION AND BACTERIAL INFECTIONS |
RU2701684C2 (en) * | 2013-10-31 | 2019-09-30 | Ридженерон Фармасьютикалз, Инк. | Competitive ligand binding assay for detecting neutralizing antibodies |
TWI713453B (en) | 2014-06-23 | 2020-12-21 | 美商健生生物科技公司 | Interferon alpha and omega antibody antagonists |
UA122673C2 (en) | 2014-11-07 | 2020-12-28 | Елевен Байотерапьютікс, Інк. | Improved il-6 antibodies |
JP2018529756A (en) * | 2015-07-31 | 2018-10-11 | メディミューン リミテッド | Methods for treating hepcidin-mediated disorders |
JP2019510078A (en) * | 2016-02-23 | 2019-04-11 | セセン バイオ, インコーポレイテッド | IL-6 antagonist preparation and use thereof |
EP3440108A4 (en) * | 2016-04-07 | 2020-01-08 | Janssen Biotech, Inc. | Treatment of depression using agents that block binding of il-6 to il-6 receptor |
WO2018144773A1 (en) * | 2017-02-01 | 2018-08-09 | Yale University | Treatment of diuretic resistance |
CA3087699A1 (en) * | 2018-01-05 | 2019-07-11 | Corvidia Therapeutics, Inc. | Methods for treating il-6 mediated inflammation without immunosuppression |
TW202019956A (en) | 2018-07-24 | 2020-06-01 | 美商麥迪紐有限責任公司 | Antibody directed against s. aureus clumping factor a (clfa) |
CA3115633A1 (en) | 2018-10-09 | 2020-04-16 | Medimmune, Llc | Combinations of anti-staphylococcus aureus antibodies |
AU2019359207A1 (en) | 2018-10-09 | 2021-05-20 | Humabs Biomed Sa | Antibodies directed against Staphylococcus aureus leukotoxins |
JP2022524420A (en) | 2019-03-13 | 2022-05-02 | メディミューン,エルエルシー | Reduction of Staphylococcus aureus infections in colonized patients |
WO2020223565A1 (en) | 2019-05-01 | 2020-11-05 | Corvidia Therapeutics, Inc. | Anti-il-6 antibody formulation |
CN111057152B (en) * | 2019-12-11 | 2022-03-11 | 中国人民解放军第四军医大学 | Anti-human IL-6Ra monoclonal antibody and application thereof |
US20230293636A1 (en) * | 2019-12-31 | 2023-09-21 | Peptinov | Pharmaceutical composition for the prevention or treatment of post-surgical pain |
WO2021186398A1 (en) | 2020-03-19 | 2021-09-23 | Medimmune Limited | Anti-klebsiella pneumoniae antibodies and uses thereof |
EP4153312A1 (en) | 2020-05-17 | 2023-03-29 | AstraZeneca UK Limited | Sars-cov-2 antibodies and methods of selecting and using the same |
AR122933A1 (en) | 2020-07-10 | 2022-10-19 | Novo Nordisk As | METHODS TO TREAT CARDIOVASCULAR DISEASE |
CN116234577A (en) | 2020-08-10 | 2023-06-06 | 阿斯利康(英国)有限公司 | SARS-COV-2 antibodies for the treatment and prevention of COVID-19 |
TW202342095A (en) | 2021-11-05 | 2023-11-01 | 英商阿斯特捷利康英國股份有限公司 | Composition for treatment and prevention of covid-19 |
WO2023209177A1 (en) | 2022-04-29 | 2023-11-02 | Astrazeneca Uk Limited | Sars-cov-2 antibodies and methods of using the same |
WO2024073718A1 (en) * | 2022-09-30 | 2024-04-04 | Sonnet BioTherapeutics, Inc. | Low dose il-6 formulations and methods of use thereof |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ297083B6 (en) * | 1998-03-17 | 2006-09-13 | Chugai Seiyaku Kabushiki Kaisha | Agent for prevention and treatment of inflammatory intestinal disease containing IL-6 antagonist as active component |
US7658921B2 (en) * | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
PT1355919E (en) * | 2000-12-12 | 2011-03-02 | Medimmune Llc | Molecules with extended half-lives, compositions and uses thereof |
WO2004039826A1 (en) * | 2001-11-14 | 2004-05-13 | Centocor, Inc. | Anti-il-6 antibodies, compositions, methods and uses |
ES2263984T3 (en) * | 2002-06-28 | 2006-12-16 | Domantis Limited | DOUBLE-SPECIFIC LINKS WITH AN INCREASED SERIOUS MIDDLE LIFE. |
SI2335725T1 (en) * | 2003-04-04 | 2017-01-31 | Genentech, Inc. | High concentration antibody and protein formulations |
US20060115485A1 (en) * | 2004-10-29 | 2006-06-01 | Medimmune, Inc. | Methods of preventing and treating RSV infections and related conditions |
JO3058B1 (en) * | 2005-04-29 | 2017-03-15 | Applied Molecular Evolution Inc | Anti-IL-6 Antibodies,Compositions,Methods and uses |
EP1896503B1 (en) * | 2005-05-31 | 2014-10-29 | Board of Regents, The University of Texas System | IgG1 ANTIBODIES WITH MUTATED Fc PORTION FOR INCREASED BINDING TO FcRn RECEPTOR AND USES TEHEREOF |
WO2007005612A2 (en) * | 2005-07-01 | 2007-01-11 | Medimmune, Inc. | An integrated approach for generating multidomain protein therapeutics |
AU2007212147A1 (en) * | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
EP2004690A2 (en) * | 2006-03-13 | 2008-12-24 | Ablynx N.V. | Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
TW200831528A (en) * | 2006-11-30 | 2008-08-01 | Astrazeneca Ab | Compounds |
EP2114451A2 (en) * | 2007-01-09 | 2009-11-11 | Wyeth a Corporation of the State of Delaware | Anti-il-13 antibody formulations and uses thereof |
BRPI0811466A2 (en) * | 2007-05-07 | 2014-10-14 | Medimmune Llc | ISOLATED ANTIBODY, NUCLEIC ACID, VECTOR, ISOLATED CELL, METHODS FOR PRODUCTING AN ANTIBODY, TO TREAT DISEASE OR DISORDER, TO TREAT OR PREVENT REJECTION IN A HUMAN TRANSPLANT PATIENT TO BE TURNED TO HUMAN, TO EXHAUST T CELLS EXPRESSING ICOS IN A HUMAN PATIENT, TO BREAK THE GERMINAL CENTER ARCHITECTURE IN A PRIMARY SECONDARY LYMPHID ORGAN, TO DEPLETE GERMAN CENTRAL LYMPHIDE ORGAN B CELLS WITH A PRIMATE BULTA IN CURRENT CLASSES IN A PRIMATE, AND, PHARMACEUTICAL COMPOSITION. |
HUE043782T2 (en) * | 2007-05-21 | 2019-09-30 | Alderbio Holdings Llc | Antibodies to il-6 and use thereof |
JP5513380B2 (en) * | 2007-06-25 | 2014-06-04 | アムジエン・インコーポレーテツド | Composition of specific binding agents for hepatocyte growth factor |
AU2008268362A1 (en) * | 2007-06-26 | 2008-12-31 | Medimmune, Llc | Methods of treating RSV infections and related conditions |
US20120034212A1 (en) * | 2009-01-29 | 2012-02-09 | Michael Bowen | Human Anti-IL-6 Antibodies With Extended In Vivo Half-Life And Their Use In Treatment Of Oncology, Autoimmune Diseases And Inflammatory Diseases |
-
2010
- 2010-01-29 US US13/146,278 patent/US20120034212A1/en not_active Abandoned
- 2010-01-29 CA CA2749200A patent/CA2749200A1/en not_active Abandoned
- 2010-01-29 SG SG2014007637A patent/SG2014007637A/en unknown
- 2010-01-29 RU RU2011135422/10A patent/RU2011135422A/en not_active Application Discontinuation
- 2010-01-29 AU AU2010208125A patent/AU2010208125B2/en active Active
- 2010-01-29 WO PCT/US2010/022478 patent/WO2010088444A1/en active Application Filing
- 2010-01-29 BR BRPI1007005A patent/BRPI1007005A2/en not_active Application Discontinuation
- 2010-01-29 MX MX2011007832A patent/MX337590B/en active IP Right Grant
- 2010-01-29 CN CN2010800103915A patent/CN102387814A/en active Pending
- 2010-01-29 SG SG2011046265A patent/SG172354A1/en unknown
- 2010-01-29 CN CN201410349897.9A patent/CN104119438A/en active Pending
- 2010-01-29 KR KR1020117019221A patent/KR20110108398A/en not_active Application Discontinuation
- 2010-01-29 EP EP10736433A patent/EP2391384A4/en not_active Ceased
- 2010-01-29 JP JP2011548315A patent/JP2012516158A/en active Pending
- 2010-01-29 RU RU2015150249A patent/RU2650594C1/en active
- 2010-01-29 SG SG10201704214VA patent/SG10201704214VA/en unknown
-
2011
- 2011-06-28 ZA ZA2011/04796A patent/ZA201104796B/en unknown
-
2012
- 2012-09-18 HK HK15102182.7A patent/HK1201847A1/en unknown
- 2012-09-27 ZA ZA2012/07249A patent/ZA201207249B/en unknown
-
2014
- 2014-04-15 US US14/253,161 patent/US20140302058A1/en not_active Abandoned
-
2015
- 2015-06-19 JP JP2015123389A patent/JP2016019517A/en active Pending
-
2016
- 2016-12-02 US US15/368,499 patent/US20170101468A1/en not_active Abandoned
-
2017
- 2017-06-07 JP JP2017112163A patent/JP2017206519A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20120034212A1 (en) | 2012-02-09 |
CA2749200A1 (en) | 2010-08-05 |
WO2010088444A1 (en) | 2010-08-05 |
BRPI1007005A2 (en) | 2016-03-22 |
SG172354A1 (en) | 2011-07-28 |
JP2012516158A (en) | 2012-07-19 |
KR20110108398A (en) | 2011-10-05 |
HK1201847A1 (en) | 2015-09-11 |
US20170101468A1 (en) | 2017-04-13 |
AU2010208125B2 (en) | 2015-02-12 |
RU2011135422A (en) | 2013-03-10 |
MX2011007832A (en) | 2011-10-06 |
MX337590B (en) | 2016-03-11 |
US20140302058A1 (en) | 2014-10-09 |
JP2017206519A (en) | 2017-11-24 |
CN102387814A (en) | 2012-03-21 |
SG2014007637A (en) | 2014-03-28 |
ZA201104796B (en) | 2018-11-28 |
EP2391384A1 (en) | 2011-12-07 |
EP2391384A4 (en) | 2012-12-26 |
CN104119438A (en) | 2014-10-29 |
JP2016019517A (en) | 2016-02-04 |
RU2650594C1 (en) | 2018-04-17 |
ZA201207249B (en) | 2013-08-28 |
AU2010208125A1 (en) | 2011-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201104796B (en) | Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology,autoimmune diseases and inflammatory diseases | |
EP2068925A4 (en) | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease | |
ZA201109384B (en) | Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases | |
IL200572A0 (en) | Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases | |
ZA201100974B (en) | Treatment of autoimmune and inflammatory disease | |
HK1245119A1 (en) | Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agents | |
IL222006A (en) | Conjugates of pyrrolobenzodiazepines and their use in therapy | |
SI2254870T1 (en) | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 | |
IL220899A (en) | Anti-cd127 antibody and use thereof in the treatment of a subject afflicted with an autoimmune or inflammatory disease | |
LT2262778T (en) | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxcr1 and p40 | |
PL2683826T3 (en) | Use of aptamers in therapy and/or diagnosis of autoimmune diseases | |
HK1148271A1 (en) | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1 and cx3cr1 1--3- mcp-1 cx3cr1 | |
HK1168283A1 (en) | Sorcs1-like agent for use in the treatment of insulin resistance and diseases related thereto sorcs1 | |
GB2460178B (en) | Depsipeptides and their therapeutic use | |
EP2420515A4 (en) | Diagnosis and treatment of cancer using anti-tmprss11e antibody | |
GB2460181B (en) | Depsipeptides and their therapeutic use | |
HRP20151393T8 (en) | USE OF BENZYDAMINE IN THE TREATMENT OF p40-DEPENDENT DISEASES | |
GB0905970D0 (en) | Depsipeptides and their therapeutic use | |
HU0900195D0 (en) | Diagnosis and treatment of gluten-induced autoimmune diseases | |
PL2265279T3 (en) | Use of the nonapeptide pat in the treatment of autoimmune diseases | |
GB2460180B (en) | Depsipeptides and their therapeutic use | |
GB0809324D0 (en) | Depsipeptides and their therapeutic use | |
GB0809330D0 (en) | Depsipeptides and their therapeutic use | |
GB0809328D0 (en) | Depsipeptides and their therapeutic use |